[PART I - FINANCIAL INFORMATION](index=6&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) [Financial Statements (Unaudited)](index=6&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents Amneal Pharmaceuticals' unaudited consolidated financial statements for the three months ended March 31, 2025, including statements of operations, balance sheets, and cash flows [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) The company reported net revenue of **$695.4 million**, a 5.5% increase, and a significant turnaround to **$100.3 million** operating income from a prior-year loss Consolidated Statements of Operations Highlights (in thousands, except per share amounts) | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | **Net revenue** | $695,420 | $659,191 | | **Gross profit** | $255,891 | $238,060 | | **Operating income (loss)** | $100,347 | $(10,746) | | **Net income (loss) attributable to Amneal** | $12,195 | $(91,643) | | **Diluted EPS** | $0.04 | $(0.30) | - The significant improvement in operating income was largely driven by the absence of a **$94.4 million** charge related to legal matters that was recorded in the first quarter of 2024[15](index=15&type=chunk) [Consolidated Balance Sheets](index=9&type=section&id=Consolidated%20Balance%20Sheets) Total assets decreased to **$3.37 billion** as of March 31, 2025, with cash and equivalents at **$59.2 million**, while total liabilities also saw a reduction Consolidated Balance Sheet Highlights (in thousands) | Metric | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $59,187 | $110,552 | | **Total current assets** | $1,510,450 | $1,587,806 | | **Total assets** | $3,365,249 | $3,501,445 | | **Total current liabilities** | $1,075,824 | $1,129,771 | | **Long-term debt, net** | $2,153,979 | $2,161,790 | | **Total liabilities** | $3,424,638 | $3,545,983 | | **Total stockholders' deficiency** | $(132,000) | $(109,512) | [Consolidated Statements of Cash Flows](index=10&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash provided by operating activities improved to **$7.4 million** for Q1 2025, compared to a **$4.4 million** use in the prior year, resulting in a **$50.0 million** net decrease in cash Consolidated Cash Flow Highlights (in thousands) | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | **Net cash provided by (used in) operating activities** | $7,408 | $(4,410) | | **Net cash used in investing activities** | $(17,798) | $(19,760) | | **Net cash used in financing activities** | $(39,166) | $(23,155) | | **Net decrease in cash, cash equivalents, and restricted cash** | $(50,026) | $(47,490) | [Notes to Consolidated Financial Statements](index=15&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) This section provides detailed disclosures on accounting policies, revenue recognition, legal contingencies, and debt, including updates on the opioid litigation settlement - Three customers (A, B, and C) accounted for **24%**, **15%**, and **21%** of total net revenue, respectively, for the three months ended March 31, 2025, indicating **significant customer concentration**[38](index=38&type=chunk) - In late April 2024, the company reached a nationwide settlement in principle for opioid cases, agreeing to pay **$92.5 million** in cash over ten years and provide **$180.0 million** in naloxone nasal spray, with a **$94.4 million** charge recorded in Q1 2024 related to this[75](index=75&type=chunk)[85](index=85&type=chunk) - In January 2025, the company paid the entire remaining principal balance of **$192.0 million** on its Term Loan Due 2025 using borrowings from its revolving credit facility and cash on hand[61](index=61&type=chunk) - Subsequent to the quarter end, the company increased its Rondo Revolving Credit Facility borrowing capacity from **$70 million** to **$125 million** and acquired land in India for **$11.4 million** from related parties to build new manufacturing facilities[112](index=112&type=chunk)[114](index=114&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=36&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's Q1 2025 financial performance, highlighting a **5.5%** increase in consolidated net revenue and a significant turnaround in operating income Consolidated Results Summary (in thousands) | Metric | Q1 2025 | Q1 2024 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | **Net revenue** | $695,420 | $659,191 | $36,229 | 5.5% | | **Gross profit** | $255,891 | $238,060 | $17,831 | 7.5% | | **Operating income (loss)** | $100,347 | $(10,746) | $111,093 | nm | | **Net income (loss)** | $24,618 | $(81,678) | $106,296 | nm | - Net revenue growth was driven by new product launches in the Affordable Medicines segment, growth in the government label channel for AvKARE, and increased sales of CREXONT® and UNITHROID® in the Specialty segment[130](index=130&type=chunk) - The company believes its cash from operations, available cash, and borrowing capacity are **sufficient** to fund operations, meet obligations, and support acquisitions over the next 12 months[154](index=154&type=chunk)[155](index=155&type=chunk) [Results of Operations](index=37&type=section&id=Results%20of%20Operations) Consolidated net revenue increased by **5.5%** to **$695.4 million**, with operating income significantly improving due to the non-recurrence of a **$94.4 million** legal charge - Affordable Medicines revenue grew **6.0%** to **$414.7 million**, driven by new products contributing **$40.8 million** in year-over-year growth[137](index=137&type=chunk) - Specialty revenue increased **2.9%** to **$108.3 million**, led by sales of CREXONT® and UNITHROID®, though partially offset by a decline in RYTARY® sales and prior-year out-licensing revenue[145](index=145&type=chunk) - AvKARE revenue rose **6.0%** to **$172.4 million**, fueled by growth in the government label channel from new product introductions[150](index=150&type=chunk) [Liquidity and Capital Resources](index=40&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity is supported by cash from operations and debt financing, with **$305.2 million** available under its main revolving credit facility and estimated **$120.0 million** in 2025 capital expenditures - As of March 31, 2025, the company had access to **$305.2 million** of available capacity under the Amended New Revolving Credit Facility and **$28.0 million** under the Amended Rondo Revolving Credit Facility[154](index=154&type=chunk) - The company estimates approximately **$120.0 million** in capital expenditures for 2025, primarily for manufacturing equipment, IT, and facilities[156](index=156&type=chunk) - The improvement in operating cash flow was primarily driven by the non-recurrence of a **$52.4 million** payment for the Opana ER® antitrust litigation settlement made in Q1 2024, along with better receivables collections[166](index=166&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=43&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) There have been no material changes in the company's assessment of market risk compared to its 2024 Annual Report on Form 10-K - There has not been any **material change** in the company's assessment of market risk as set forth in its 2024 Annual Report on Form 10-K[173](index=173&type=chunk) [Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal control over financial reporting - Based on an evaluation as of the end of the period, the Co-Chief Executive Officers and Chief Financial Officer concluded that the company's disclosure controls and procedures were **effective** as of March 31, 2025[175](index=175&type=chunk) - **No changes** in internal control over financial reporting occurred during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, internal controls[176](index=176&type=chunk) [PART II - OTHER INFORMATION](index=45&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Legal Proceedings](index=45&type=section&id=Item%201.%20Legal%20Proceedings) Information regarding legal proceedings is incorporated by reference from **Note 16, Commitments and Contingencies**, of the financial statements - Information regarding legal proceedings is located in **Note 16. Commitments and Contingencies**[179](index=179&type=chunk) [Risk Factors](index=45&type=section&id=Item%201A.%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's 2024 Annual Report on Form 10-K - There have been **no material changes** to the risk factors previously disclosed in the 2024 Annual Report on Form 10-K[180](index=180&type=chunk) [Exhibits](index=46&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including an employment agreement, Sarbanes-Oxley Act certifications, and iXBRL data files - Exhibits filed include an **employment agreement** for Jason Daly, **Sarbanes-Oxley Act certifications**, and **iXBRL formatted financial statements**[186](index=186&type=chunk)

Amneal Pharmaceuticals (AMRX) reported $695.42 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 5.5%. EPS of $0.21 for the same period compares to $0.14 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $714.78 million, representing a surprise of -2.71%. The company delivered an EPS surprise of +40.00%, with the consensus EPS estimate being $0.15.While investors scrutinize revenue and earnings changes year-over-year and how they compare ...

Financial Data and Key Metrics Changes - In Q1 2025, total net revenues reached $695 million, reflecting a 5% growth year-over-year [4][27] - Adjusted EBITDA for the same period was $170 million, which represents a 12% increase [4][29] - Adjusted EPS grew by 50%, reaching $0.21, driven by higher adjusted EBITDA and lower interest expenses [29] Business Line Data and Key Metrics Changes - Affordable Medicines segment generated $415 million in revenue, up 6% from the previous year, with new product launches contributing $41 million [28] - Specialty segment revenue was $108 million, a 3% increase, primarily driven by the performance of Crexon and Unitroid [28] - AvKARE revenues were $172 million, also growing by 6%, although growth was partially offset by softness in the lower-margin distribution channel [28] Market Data and Key Metrics Changes - The specialty segment's Crexon for Parkinson's disease has surpassed 1% market share and is projected to exceed 3% by year-end [7] - Trexond's market access has expanded significantly, increasing coverage from approximately 30% to 60% of U.S. covered lives [8] - The healthcare segment is expected to reach over $900 million in revenue by 2027, driven by new launches across various channels [14] Company Strategy and Development Direction - The company aims to be a leader in affordable medicines, focusing on innovation, quality, and operational excellence [5][15] - Amneal is expanding its specialty branded portfolio and anticipates launching a DHE auto injector later this year [9][21] - The strategic partnership with MedCera in the GLP-1 space is expected to drive long-term growth through new manufacturing facilities [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving U.S. peak sales of $300 to $500 million for Trexon, highlighting strong market uptake [9] - The company is well-positioned to address drug shortages and expand its manufacturing capabilities in the U.S. [18] - Management affirmed full-year 2025 guidance, expecting total net revenue between $3 billion and $3.1 billion, reflecting 7% to 11% growth [32] Other Important Information - The company has a robust pipeline with 81 ANDAs pending approval, of which 65% are non-oral solids [23] - Amneal's biosimilars strategy includes filing for five additional biosimilars this year, with a goal of having six biosimilars on the market by 2027 [14][25] - The company is investing in digitization and automation to enhance operational efficiency [18] Q&A Session Summary Question: What is the expected top-line contribution from biosimilars? - Management expects around $105 to $110 million in total contribution from biosimilars, with Alimsys projected to contribute between $90 to $100 million [36][39] Question: When will vertical integration for biosimilars occur? - Vertical integration options are expected to be executed by the end of this year or early next year, with significant long-term contributions anticipated [40] Question: What is the focus between complex products and drug shortages in injectables? - The company is focusing equally on both areas, with a robust pipeline of complex injectables and ongoing efforts to address drug shortages [45][46] Question: How exposed is AskHARE to federal government cuts? - The federal cuts do not apply to the VA, which is expanding, leading to volume growth in that segment [51] Question: Are there any FDA delays in approvals or feedback? - Management reported no delays from the FDA at this point, with all products progressing well [54] Question: How would tariffs impact the company's manufacturing strategy? - The company has additional capacity in the U.S. and would leverage this if tariffs were applied, while also considering price increases in collaboration with major customers [59][60]

Financial Data and Key Metrics Changes - In Q1 2025, total revenues reached $695 million, reflecting a 5% growth year-over-year [4][28] - Adjusted EBITDA for the quarter was $170 million, which is a 12% increase compared to the previous year [4][30] - Adjusted EPS grew by 50%, reaching $0.21, driven by higher adjusted EBITDA and lower interest expenses [30] Business Line Data and Key Metrics Changes - Affordable Medicines segment generated $415 million in revenue, up 6%, with new product launches contributing $41 million [29] - Specialty segment revenue was $108 million, a 3% increase, primarily driven by the performance of Crexon and Unitroid [29] - AvKARE revenues were $172 million, growing 6%, with strong growth in the government channel [29] Market Data and Key Metrics Changes - The specialty segment's market share for Crexon has surpassed 1% and is projected to exceed 3% by the end of the year [7] - Trexon has achieved approximately 60% coverage of US lives, doubling from 30% in February [8] - The healthcare segment is expected to reach over $900 million in revenue by 2027 [15] Company Strategy and Development Direction - The company aims to be a leader in affordable medicines, focusing on innovation, quality, and operational excellence [5][16] - Amneal is expanding its specialty branded portfolio and anticipates launching a DHE auto injector later this year [9][21] - The strategic partnership with MedCera in the GLP-1 space is expected to drive long-term growth through new manufacturing facilities [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving peak sales of $300 to $500 million for Trexon and highlighted the strong market uptake of Crexon [9][27] - The company is well-positioned to address drug shortages and enhance patient access through its robust manufacturing capabilities [18][19] - Management affirmed full-year 2025 expectations, projecting total net revenue between $3 billion and $3.1 billion, reflecting 7% to 11% growth [33] Other Important Information - The company has a diverse array of growth drivers, including biosimilars, injectables, and specialty products [15][26] - Amneal has filed regulatory applications for five additional biosimilars this year, with a goal of having six biosimilars on the market by 2027 [14][25] Q&A Session Summary Question: What is the expected top-line contribution from biosimilars? - Management expects a total contribution of around $105 to $160 million from biosimilars, with Alimpsus projected to contribute between $90 to $100 million [40][41] Question: When will vertical integration for biosimilars occur? - Vertical integration is expected to be executed by the end of this year or early next year, with a focus on establishing a significant presence in the biosimilars market [41][42] Question: What is the focus between complex products and drug shortages in injectables? - The company is focusing equally on both complex products and addressing drug shortages, with a robust pipeline of injectable products [45][46]

Core Viewpoint - Amneal Pharmaceuticals reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.15 per share, and showing an increase from $0.14 per share a year ago, indicating a 40% earnings surprise [1][2] Financial Performance - The company posted revenues of $695.42 million for the quarter ended March 2025, which was 2.71% below the Zacks Consensus Estimate, but an increase from $659.19 million year-over-year [2] - Over the last four quarters, Amneal has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Amneal shares have declined approximately 2.3% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $767.5 million, and for the current fiscal year, it is $0.68 on revenues of $3.03 billion [7] - The outlook for the Medical - Drugs industry, where Amneal operates, is favorable, ranking in the top 26% of over 250 Zacks industries, suggesting potential for outperformance [8]

Earnings Call Q1 2025 May 2, 2025 1 Cautionary statement on forward looking statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; ex ...

[Q1 2025 Financial Performance Overview](index=1&type=section&id=AMNEAL%20REPORTS%20FIRST%20QUARTER%202025%20FINANCIAL%20RESULTS) [First Quarter 2025 Financial Highlights](index=1&type=section&id=First%20Quarter%202025%20Results) Amneal reported strong Q1 2025 results, with a 5% increase in net revenue to $695 million, achieving a significant turnaround with a net income of $12 million compared to a $92 million loss in the prior-year quarter, largely due to the absence of a 2024 legal settlement charge, while Adjusted EBITDA grew by 12% to $170 million and Adjusted Diluted EPS increased by 50% to $0.21, reflecting broad-based growth across all segments and strong operational execution Q1 2025 Key Financial Metrics vs. Q1 2024 | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Net Revenue | $695 million | $659 million | +5% | | Net Income (Loss) | $12 million | ($92 million) | N/A | | Diluted EPS | $0.04 | ($0.30) | N/A | | Adjusted EBITDA | $170 million | $152 million (est.) | +12% | | Adjusted Diluted EPS | $0.21 | $0.14 | +50% | - Growth was driven by all three business segments: - **Affordable Medicines:** +6% driven by complex products and new launches - **Specialty:** +3% driven by key brands like CREXONT® and UNITHROID® - **AvKARE:** +6% driven by growth in government label sales[3](index=3&type=chunk) - The significant improvement in net income from a loss of **$92 million loss** in Q1 2024 to a profit of **$12 million** in Q1 2025 was primarily due to a **$94 million legal settlement charge** recorded in the prior-year period[4](index=4&type=chunk) - Management highlighted the strong commercial uptake of CREXONT® for Parkinson's Disease and the positive momentum of recently launched injectable products[2](index=2&type=chunk) [Full Year 2025 Financial Guidance](index=1&type=section&id=Affirming%20Full%20Year%202025%20Financial%20Guidance) Amneal has reaffirmed its full-year 2025 financial guidance, projecting net revenue between $3.0 billion and $3.1 billion, with Adjusted EBITDA expected to be in the range of $650 million to $675 million Full Year 2025 Guidance | Metric | Guidance Range | | :--- | :--- | | Net revenue | $3.0 billion - $3.1 billion | | Adjusted EBITDA | $650 million - $675 million | | Adjusted diluted EPS | $0.65 - $0.70 | | Operating cash flow | $255 million - $285 million | | Capital expenditures | Approx. $100 million | [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) For the first quarter of 2025, net revenue increased to $695.4 million from $659.2 million in Q1 2024, with the company reporting operating income of $100.3 million, a substantial recovery from an operating loss of $10.7 million in the prior-year quarter mainly due to the absence of a significant legal charge, resulting in net income attributable to Amneal of $12.2 million, or $0.04 per diluted share Q1 2025 vs Q1 2024 Statement of Operations (in thousands) | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net revenue | $695,420 | $659,191 | | Gross profit | $255,891 | $238,060 | | Charges related to legal matters, net | $0 | $94,359 | | Operating income (loss) | $100,347 | ($10,746) | | Net income (loss) attributable to Amneal | $12,195 | ($91,643) | | Diluted income (loss) per share | $0.04 | ($0.30) | [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, Amneal's total assets were $3.37 billion, a decrease from $3.50 billion at year-end 2024, with cash and cash equivalents at $59.2 million, down from $110.6 million, and total debt approximately $2.48 billion, while the revolving credit facility balance increased to $290 million from $100 million Balance Sheet Highlights (in thousands) | Line Item | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $59,187 | $110,552 | | Total current assets | $1,510,450 | $1,587,806 | | Total assets | $3,365,249 | $3,501,445 | | Revolving credit facility | $290,000 | $100,000 | | Total long-term debt, net | $2,153,979 | $2,161,790 | | Total liabilities | $3,424,638 | $3,545,983 | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, the company generated $7.4 million in cash from operating activities, an improvement from $4.4 million used in Q1 2024, with cash used in investing activities at $17.8 million and cash used in financing activities at $39.2 million primarily due to debt repayments exceeding borrowings on the revolver, resulting in a net decrease in cash of $50.0 million for the quarter Q1 2025 vs Q1 2024 Cash Flow Summary (in thousands) | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $7,408 | ($4,410) | | Net cash used in investing activities | ($17,798) | ($19,760) | | Net cash used in financing activities | ($39,166) | ($23,155) | | Net decrease in cash | ($50,026) | ($47,490) | | Cash, cash equivalents, and restricted cash - end of period | $68,394 | $51,617 | [Segment Performance](index=13&type=section&id=Segment%20Performance) [Affordable Medicines Segment](index=13&type=section&id=Affordable%20Medicines%20Segment) The Affordable Medicines segment reported a 6% year-over-year increase in net revenue to $414.7 million for Q1 2025, with its non-GAAP gross margin improving to 44.1% from 41.8%, and non-GAAP operating income growing significantly to $124.2 million from $97.6 million in Q1 2024 Affordable Medicines Q1 Performance (in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Revenue | $414,708 | $391,294 | | Non-GAAP Gross Profit | $182,950 | $163,640 | | Non-GAAP Gross Margin % | 44.1% | 41.8% | | Non-GAAP Operating Income | $124,169 | $97,608 | [Specialty Segment](index=14&type=section&id=Specialty%20Segment) The Specialty segment's net revenue increased by 3% to $108.3 million in Q1 2025, however, its non-GAAP operating income decreased to $48.9 million from $56.8 million in the prior-year quarter, with a slight dip in non-GAAP gross margin to 81.1% Specialty Segment Q1 Performance (in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Revenue | $108,297 | $105,234 | | Non-GAAP Gross Profit | $87,854 | $86,412 | | Non-GAAP Gross Margin % | 81.1% | 82.1% | | Non-GAAP Operating Income | $48,898 | $56,820 | [AvKARE Segment](index=15&type=section&id=AvKARE%20Segment) The AvKARE segment posted net revenue of $172.4 million in Q1 2025, a 6% increase from Q1 2024, with gross margin improving slightly to 16.6%, and operating income growing to $12.9 million from $11.3 million year-over-year AvKARE Segment Q1 Performance (in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Revenue | $172,415 | $162,663 | | Gross Profit | $28,602 | $26,254 | | Gross Margin % | 16.6% | 16.1% | | Operating Income | $12,908 | $11,347 | [Non-GAAP Financial Measures & Reconciliations](index=3&type=section&id=Non-GAAP%20Financial%20Measures) [Reconciliation of Net Income to Adjusted EBITDA](index=8&type=section&id=Reconciliation%20of%20Net%20Income%20(Loss)%20to%20EBITDA%20and%20Adjusted%20EBITDA) For Q1 2025, Amneal reconciled its GAAP Net Income of $24.6 million to a non-GAAP Adjusted EBITDA of $170.0 million, representing a 12% increase from the $152.4 million Adjusted EBITDA in Q1 2024, with primary adjustments including adding back interest, taxes, depreciation & amortization, and other non-cash or non-recurring items Q1 2025 Reconciliation to Adjusted EBITDA (in thousands) | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net income (loss) | $24,618 | ($81,678) | | Interest, Taxes, D&A | $129,966 | $127,387 | | EBITDA (Non-GAAP) | $154,584 | $45,709 | | Other Adjustments (Legal, Stock Comp, etc.) | $15,394 | $106,642 | | **Adjusted EBITDA (Non-GAAP)** | **$169,978** | **$152,351** | [Reconciliation of Net Income to Adjusted Net Income & EPS](index=11&type=section&id=Reconciliation%20of%20Net%20Income%20(Loss)%20to%20Adjusted%20Net%20Income%20and%20Calculation%20of%20Adjusted%20Diluted%20Earnings%20Per%20Share) The company adjusted its Q1 2025 GAAP Net Income of $24.6 million to arrive at a non-GAAP Adjusted Net Income of $66.5 million, resulting in an Adjusted Diluted EPS of $0.21, marking a 50% increase from the $0.14 reported in Q1 2024, with key adjustments including amortization, stock-based compensation, and tax-related items Q1 2025 Reconciliation to Adjusted Diluted EPS | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net income (loss) | $24,618 | ($81,678) | | Total Adjustments | $41,925 | $126,158 | | **Adjusted net income (Non-GAAP)** | **$66,543** | **$44,480** | | Weighted average diluted shares | 323,961 | 316,559 | | **Adjusted diluted EPS (Non-GAAP)** | **$0.21** | **$0.14** | [Calculation of Net Leverage](index=9&type=section&id=Calculation%20of%20Net%20Leverage) As of March 31, 2025, Amneal's net debt stood at $2.51 billion, with the company's net leverage ratio at 3.9x, calculated against a last-twelve-months (LTM) Adjusted EBITDA of $645.1 million, remaining unchanged from the end of the 2024 fiscal year Net Leverage Calculation | Metric | As of March 31, 2025 | As of December 31, 2024 | | :--- | :--- | :--- | | Gross debt | $2,568,158 thousand | $2,584,835 thousand | | Less: Cash and cash equivalents | $59,197 thousand | $110,552 thousand | | **Net debt (Non-GAAP)** | **$2,508,961 thousand** | **$2,474,283 thousand** | | LTM Adjusted EBITDA | $645,069 thousand | $627,442 thousand | | **Net leverage (Non-GAAP)** | **3.9x** | **3.9x** |

Company Overview - Amneal Pharmaceuticals (AMRX) is expected to report a year-over-year increase in earnings, with a projected EPS of $0.15, reflecting a change of +7.1% [3] - Revenues are anticipated to reach $714.78 million, representing an 8.4% increase from the previous year [3] Earnings Expectations - The consensus EPS estimate has been revised 3.23% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The company has an Earnings ESP of +2.27%, suggesting a likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Amneal's actual earnings were $0.12 per share, which was a -20% surprise compared to the expected $0.15 [12] - Over the last four quarters, Amneal has beaten consensus EPS estimates three times [13] Market Sentiment - The upcoming earnings report is set to be released on May 2, and the stock may move higher if the results exceed expectations [2] - The combination of a positive Earnings ESP and a Zacks Rank of 3 indicates a favorable outlook for Amneal's earnings performance [11]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Debt and Liquidity - As of December 31, 2024, the company had approximately $2.6 billion in total indebtedness[234] - In January 2025, the company paid off $192.0 million of its Term Loan Due 2025, along with $0.7 million in accrued interest, using $190.0 million from new borrowings and cash on hand[234] - The company expects to make $58.8 million in principal payments on the Term Loan Due 2028 during 2025, with interest payments totaling $226.9 million for the same loan[234] - The company faces substantial liquidity risks if cash flows are insufficient to meet debt service obligations, potentially leading to asset disposals or restructuring[235] - Credit agreements impose restrictions on the company's operations, including limitations on incurring additional debt and paying dividends[236] - The company has $2.5 billion in term loans, with an Amended New Revolving Credit Facility allowing loans and letters of credit up to $495.2 million and $28.0 million, respectively[381] - As of December 31, 2024, the company had $2.48 billion in variable rate debt, including a Term Loan Due 2028 with $2.29 billion and a Term Loan Due 2025 with $192.0 million outstanding[386] Tax and Regulatory Risks - The company is subject to increased tax liabilities due to operations in multiple jurisdictions, including potential challenges from tax authorities[247] - The company recorded expenses associated with the Tax Receivable Agreement (TRA) of $50.7 million, $3.1 million, and $0.6 million for the years ended December 31, 2024, 2023, and 2022, respectively[256] - As of December 31, 2024 and 2023, the company had a TRA liability of $53.9 million and $3.7 million, respectively[256] - The unrecorded contingent TRA liability as of December 31, 2024, is approximately $133.8 million, which could significantly impact future results if deferred tax assets become realizable[256] Operational and Market Challenges - The company has significantly expanded its operations in India and may continue to grow internationally, facing regulatory and economic uncertainties[241] - Generic pharmaceuticals are experiencing regular price erosion, emphasizing the need for continual new product introductions to maintain revenue[254] - The company may face significant impairment charges if goodwill and intangible assets are determined to be impaired, which could adversely affect financial results[253] Interest Rate and Currency Risks - The company is exposed to foreign exchange rate fluctuations, particularly with the Euro and Indian Rupee, which could impact cash flow and earnings[383] - The company has entered into an interest rate lock agreement for a total notional amount of $1.3 billion to manage interest rate risk associated with its LIBOR-based borrowing[387] - The company executed an amendment to the interest rate swap, changing the reference rate from LIBOR to SOFR, with a new fixed rate of 2.7877% and a termination date extended to May 4, 2027, while maintaining a notional amount of $1.3 billion[388] - The fair value of the variable-to-fixed interest rate swap was an asset of $35.9 million as of December 31, 2024[388] - A hypothetical 100 basis point increase in the forward one-month SOFR curve could increase the fair value of the swap asset by $27.0 million, while a decrease could decrease it by $28.2 million[388] - A hypothetical 100 basis point increase or decrease in interest rates would affect the annual interest expense related to the Term Loan Due 2028 by approximately $22.9 million[389] - For the Term Loan Due 2025, a similar interest rate change would affect the annual interest expense by approximately $1.9 million[389] Dividend Policy - The company does not anticipate paying any cash dividends in the foreseeable future, focusing instead on retaining earnings for business growth[267] Inflation Impact - The company expects no material impact from inflation for the year ending December 31, 2025, although rising costs could adversely affect future operating results[384]